Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will present preclinical data for the company’s programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61^st Annual American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla.

Details of the new data being presented in a poster at ASH are as follows:

Title: Complementary base editing approaches for the treatment of sickle cell disease and Beta-thalassemia

Date & Time: Sunday, December 8, 2019, 6:00-8:00 p.m. ET

Poster Session: 801 – Gene Therapy and Transfer: Poster II

Location: Orange County Convention Center, Hall B

Presenter: Ling Lin, Ph.D., senior scientist II, Beam Therapeutics

About Beam Therapeutics

Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.

Contacts

Media:

Dan Budwick

1AB

[email protected]

Investors:

Monique Allaire

THRUST Strategic Communications

[email protected]